Genmab
GMAB
133 hedge funds and large institutions have $564M invested in Genmab in 2019 Q4 according to their latest regulatory filings, with 50 funds opening new positions, 41 increasing their positions, 27 reducing their positions, and 13 closing their positions.
285% more first-time investments, than exits
New positions opened: 50 | Existing positions closed: 13
52% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 27
37% more funds holding
Funds holding: 97 → 133 (+36)
11% more capital invested
Capital invested by funds: $511M → $564M (+$53.8M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2.36% less ownership
Funds ownership: 38.78% → 36.42% (-2.4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$7.55M |
| 2 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$5.33M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$4.29M |
| 4 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$4.2M |
| 5 |
FAM
Fred Alger Management
New York
|
+$4.08M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$15.6M |
| 2 |
HM
HealthCor Management
New York
|
-$14.1M |
| 3 |
TIP
Torray Investment Partners
Bethesda,
Maryland
|
-$11.8M |
| 4 |
RG
Redmile Group
San Francisco,
California
|
-$6.81M |
| 5 |
SIG
Senator Investment Group
New York
|
-$6.58M |
GMAB Hedge Fund Activity: Q4 2019 in Review
133 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Genmab (GMAB) for Q4 2019, worth a combined $564M — up 11% from $511M a quarter earlier.
Buyers outnumbered sellers: 50 funds opened new GMAB positions and 13 closed out — a net gain of 37 holders — while 41 added to existing stakes and 27 trimmed.
The largest buyer was BlackRock, adding an estimated $7.55M. The largest seller was Citadel Advisors, cutting an estimated $15.6M.
- 133 institutional investors held Genmab (GMAB) as of Q4 2019, up from 97 in Q3 2019.
- Funds reported $564M of Genmab stock for Q4 2019, up 11% quarter-over-quarter.
- 50 funds opened new Genmab positions in Q4 2019 and 13 closed out, a net change of +37 holders.
- The largest Genmab buyer in Q4 2019 was BlackRock, an estimated $7.55M added.
- The largest Genmab seller in Q4 2019 was Citadel Advisors, an estimated $15.6M sold.
Based on aggregated 13F filings for Q4 2019.